Free Trial
NYSE:NVS

Novartis (NVS) Stock Price, News & Analysis

Novartis logo
$131.78 +0.35 (+0.27%)
Closing price 10/20/2025 03:59 PM Eastern
Extended Trading
$131.24 -0.54 (-0.41%)
As of 08:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Novartis Stock (NYSE:NVS)

Advanced

Key Stats

Today's Range
$130.60
$132.21
50-Day Range
$119.34
$132.41
52-Week Range
$96.06
$133.55
Volume
1.38 million shs
Average Volume
1.58 million shs
Market Capitalization
$278.38 billion
P/E Ratio
19.18
Dividend Yield
1.97%
Price Target
$120.33
Consensus Rating
Hold

Company Overview

Novartis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

NVS MarketRank™: 

Novartis scored higher than 51% of companies evaluated by MarketBeat, and ranked 533rd out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Novartis has received a consensus rating of Hold. The company's average rating score is 2.10, and is based on 2 buy ratings, 4 hold ratings, and 3 sell ratings.

  • Downside Risk

    Novartis has a consensus price target of $120.33, representing about 8.7% downside from its current price of $131.78.

  • Amount of Analyst Coverage

    Novartis has only been the subject of 4 research reports in the past 90 days.

  • Read more about Novartis' stock forecast and price target.
  • Earnings Growth

    Earnings for Novartis are expected to grow by 4.26% in the coming year, from $8.45 to $8.81 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Novartis is 19.18, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 43.36.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Novartis is 19.18, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.48.

  • Price to Earnings Growth Ratio

    Novartis has a PEG Ratio of 1.82. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Novartis has a P/B Ratio of 6.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Novartis' valuation and earnings.
  • Percentage of Shares Shorted

    0.23% of the float of Novartis has been sold short.
  • Short Interest Ratio / Days to Cover

    Novartis has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Novartis has recently increased by 1.87%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Novartis pays a meaningful dividend of 1.98%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Novartis does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Novartis is 37.85%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Novartis will have a dividend payout ratio of 29.51% next year. This indicates that Novartis will be able to sustain or increase its dividend.

  • Read more about Novartis' dividend.
  • Percentage of Shares Shorted

    0.23% of the float of Novartis has been sold short.
  • Short Interest Ratio / Days to Cover

    Novartis has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Novartis has recently increased by 1.87%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Novartis has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 26 news articles for Novartis this week, compared to 23 articles on an average week.
  • Search Interest

    19 people have searched for NVS on MarketBeat in the last 30 days. This is an increase of 12% compared to the previous 30 days.
  • MarketBeat Follows

    10 people have added Novartis to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Novartis insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.01% of the stock of Novartis is held by insiders.

  • Percentage Held by Institutions

    Only 13.12% of the stock of Novartis is held by institutions.

  • Read more about Novartis' insider trading history.
Receive NVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NVS Stock News Headlines

This dark force is about to change everything
An unstoppable force is reshaping America — one so powerful it’s already disrupting how we work, invest, and live. Porter Stansberry calls it The Final Displacement — a rare turning point that’s only happened four times in human history, each one redefining entire eras. His new documentary reveals why this shift could trigger both immense loss and unprecedented opportunity, and what you can do to prepare before it accelerates.tc pixel
See More Headlines

NVS Stock Analysis - Frequently Asked Questions

Novartis' stock was trading at $97.31 on January 1st, 2025. Since then, NVS shares have increased by 35.4% and is now trading at $131.7810.

Novartis AG (NYSE:NVS) announced its quarterly earnings data on Thursday, July, 17th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.38 by $0.04. The business's quarterly revenue was up 12.3% compared to the same quarter last year.
Read the conference call transcript
.

Novartis subsidiaries include Gyroscope Therapeutics, Arctos Medical, Cellerys, Cadent Therapeutics, Vedere Bio, Vedere Bio ll, Amblyotech, and more.

Novartis' top institutional shareholders include Douglas Lane & Associates LLC (0.01%), Allspring Global Investments Holdings LLC (0.01%), Euro Pacific Asset Management LLC and Ethic Inc..

Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Novartis investors own include BlackRock (BLK), Broadcom (AVGO), UnitedHealth Group (UNH), ServiceNow (NOW), Humana (HUM), TotalEnergies (TTE) and American Water Works (AWK).

Company Calendar

Last Earnings
7/17/2025
Today
10/21/2025
Next Earnings (Estimated)
10/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Large Cap Pharma
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:NVS
CIK
1114448
Employees
75,883
Year Founded
1996

Price Target and Rating

High Price Target
$123.00
Low Price Target
$118.00
Potential Upside/Downside
-8.7%
Consensus Rating
Hold
Rating Score (0-4)
2.10
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
$6.87
Trailing P/E Ratio
19.18
Forward P/E Ratio
15.60
P/E Growth
1.82
Net Income
$11.94 billion
Net Margins
25.64%
Pretax Margin
29.30%
Return on Equity
41.08%
Return on Assets
16.83%

Debt

Debt-to-Equity Ratio
0.53
Current Ratio
0.82
Quick Ratio
0.62

Sales & Book Value

Annual Sales
$50.32 billion
Price / Sales
5.53
Cash Flow
$10.73 per share
Price / Cash Flow
12.28
Book Value
$21.59 per share
Price / Book
6.10

Miscellaneous

Outstanding Shares
2,112,420,000
Free Float
2,112,211,000
Market Cap
$278.38 billion
Optionable
Optionable
Beta
0.64

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NYSE:NVS) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners